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Abstract
Background: Persister cells comprise a phenotypic variant that shows extreme antibiotic tolerance resulting in
treatment failures of bacterial infections. While this phenomenon has posed a great threat in public health,
mechanisms underlying their formation in Staphylococcus aureus remain largely unknown. Increasing evidences of
the presence of persister cells in recalcitrant infections underscores the great urgency to unravel the mechanism by
which these cells develop. Previously, we characterized msaABCR operon that plays roles in regulation of virulence,
biofilm development and antibiotic resistance. We also characterized the function of MsaB protein and showed that
MsaB is a putative transcription factor that binds target DNA in response to nutrients availability.
Results: In this study, we compared the number of persister cell in wild type, msaABCR deletion mutant and the
complemented strain in two backgrounds USA300 LAC and Mu50. Herein, we report that msaABCR deletion mutant
forms significantly less number of persister cells relative to wild type after challenge with various antibiotics in planktonic
and biofilm growth conditions. Complementation of the msaABCR operon restored wild type phenotype. Combined
antibiotic therapy along with msaABCR deletion significantly improves the killing kinetics of stationary phase and biofilm
S. aureus cells. Transcriptomics analysis showed that msaABCR regulates several metabolic genes, transcription factors,
transporters and enzymes that may play role in persister cells formation, which we seek to define in the future.
Conclusions: This study presented a new regulator, msaABCR operon, that is involved in the persister cells formation, which
is a poorly understood in S. aureus. Indeed, we showed that msaABCR deletion significantly reduces the persister cells
formation in all growth phases tested. Although, we have not yet defined the mechanism, we have shown that msaABCR
regulates several metabolic, transporters, and extracellular proteases genes that have been previously linked with persister
cells formation in other bacterial systems. Taken together, this study showed that inactivation of the msaABCR operon
enhances the effectiveness of antibiotics for the treatment of S. aureus infections, especially in context of persister cells.
Keywords: msaABCR operon, Persister cells, Stationary phase, Biofilm, Killing curve, Microfluidics, Gene ontology

Background
Staphylococcus aureus is an opportunistic human pathogen
that colonizes more than 30% of healthy individuals worldwide [1]. This pathogen is the leading cause of nosocomial
and community-associated infections, which can range from
mild superficial skin infections to life-threatening infections
(e.g. severe sepsis, bacteremia) and chronic biofilmassociated infections (e.g. osteomyelitis, implant-associated
heart valve and native valve endocarditis) [2, 3]. Several factors contribute to the ability of S. aureus to be a recalcitrant
pathogen. These factors include acquisition of antibiotic
resistance, as well as its adaptation to diverse host
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environments, biofilm formation, and development of antibiotic tolerant persister cells [2, 4–9].
Treatment failures in S. aureus infections have been
traditionally associated with antibiotic resistance; however,
in the past decades, several studies have shown that drug
tolerance and development of persister cells are also
significant contributors [4, 8, 10–15]. Tolerance is the
ability of a pathogen to survive transient exposure to lethal
doses of antibiotics without a change in the minimum
inhibitory concentration (MIC). Persistence is the ability
of a subpopulation of the pathogen to survive lethal doses
of antibiotics without any associated genetic changes
[16–18]. Persister cells are dormant or phenotypic
variant sub-populations that arise stochastically during
the exponential growth phase, but they also arise
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during the stationary growth phase and within biofilms
[5]. Previous study has shown that almost all stationary
phase S. aureus cells are tolerant to conventional drugs [4],
thus behaving as persister cells because of their characteristic slow and non-growing phenotype. In addition, some
recent studies have shown that stationary and biofilm cells
of S. aureus exhibit high cell density environment, deprived
of nutrients, oxygen, and reduced intracellular ATP
concentrations are the major determinants of persister cells
[5, 19–21]. However, the mechanism for this antibiotic
tolerance and persister cells formation is still not well
understood, especially in S. aureus.
Biofilms also provide a similar conducive environment
that favors the formation of persister cells by triggering
pathways in response to several signals, such as dormancy
within niches of biofilm, nutrient heterogeneity, quorum
signaling, and oxidative stress [13, 22–30]. Studies have indicated that persister cells within biofilms are major contributors to treatment failures and recurrent infections [5,
10]. The formation of persister cells is common to most
pathogens; however, the underlying mechanism remains
poorly understood, especially in Gram-positive bacteria.
Indeed, most studies on persister cells have been performed in Escherichia coli. Several pathways have been implicated in persistence, including toxin-antitoxin systems,
signal transduction, SOS response and DNA repair, energy
production, phosphate metabolism, membrane stress, and
protein degradation [28, 30–37]. Though the persister
phenotype was first described in the 1940s for S. aureus,
very little is known about the underlying mechanism. A
systematic, high-throughput screening in S. aureus showed
that the regulation and production of metabolites are important for bacterial persistence to stresses and antibiotics
[38]. Another study showed that ATP plays a crucial role
in persister formation in S. aureus [19]. The same study
found that known toxin/anti-toxin systems and stringent
responses are not involved in S. aureus persistence [19].
Yee et al. [38] identified several genes that have been associated with formation of persister cells in S. aureus in the
presence of rifampicin stress; however, an understanding
of the detailed mechanism responsible for persister cell
formation is still lacking.
The msaABCR operon has a critical role in biofilm development, regulation of virulence factors (proteases, pigmentation, capsule), and antibiotic resistance in S. aureus [39–41].
Previously, we showed that deletion of msaABCR operon in
S. aureus increases protease production that leads to increased processing of the major autolysin (Atl). Uncontrolled
processed major autolysin caused increased autolysis of cells
and is responsible for the defective biofilm formation [41]. In
another study, we showed that deletion of the msaABCR
operon in vancomycin-intermediate S. aureus (VISA) strains
causes significant reduction in the cell wall thickness and
leads to increased susceptibility to vancomycin [42]. We have
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not defined the mechanism of cell wall biosynthesis regulation by the msaABCR operon yet; however, we have recently
characterized MsaB, as a transcription activator for the
capsule operon and putatively for other genes that are
regulated by MsaB [39]. All our previous studies showed that
msaABCR operon is linked with several important
phenotypes like cell wall thickness, pigmentation, capsule
production, and in biofilm development that are important
to cope with stress environment. So, in this study, we examined the role of this operon in response to clinically relevant
antibiotics stress and its role in persister cell formation. We
studied persister cells formation in planktonic (exponential
and stationary) and biofilm growth conditions. Since all the
traditional drugs are ineffective against S. aureus stationary
phase cells and biofilm [5, 19, 21]; we also used combination
of drugs to study the persister cells under these stresses.

Methods
Preparation of bacterial strains and cultures

In this study, we used S. aureus strains USA300 LAC (Wild
type, msaABCR deletion mutant, and complementation
strains) and Mu50 (Wild type, msaABCR deletion mutant,
and complementation strains). We used pKOR1 based
allelic gene replacement method to construct a nonpolar,
in-frame deletion of msaABCR operon from USA300 LAC
strains as described previously [41]. Deletion of gene was
verified by end-point and real-time quantitative PCR
(qPCR), as described previously [41]. The complementation
plasmid was constructed by amplifying a copy of wild type
msaABCR operon gene with its native promoter (1788-bp
fragment with complete 5′ and 3′ untranslated regions)
and ligated to pCN34 (NARSA) [41]. The complementation
plasmid construct was transduced into the msaABCR
deletion mutant [41]. Overnight bacterial cultures were
prepared by inoculating cells from frozen culture stocks
into culture tubes containing 5 mL of freshly prepared
tryptic soy broth (TSB) or Mueller-Hinton Broth (MHB,
supplemented with 50 mM CaCl2 for daptomycin) and
incubating at 37 °C with continuous shaking at 225 rpm.
The overnight cultures were diluted 1:10 in fresh medium,
incubated further for 2 h, and then normalized to an optical
density at 600 nm (OD600) of 0.05 in pre-warmed 10 mL
MHB in 125 conical flasks to use as the starting culture.
The starting bacterial cells were grown until they reached
an OD600 of 0.5 for exponential phase and grown for an
additional 16 h for stationary cell cultures. Biofilm
formation assays were performed in biofilm media (TSB
supplemented with 3% sodium chloride and 0.5% glucose).
Antibiotic susceptibility assay

All the antibiotics (daptomycin, vancomycin, linezolid, rifampicin and gentamicin) used in this study were purchased
from Sigma-Aldrich, Inc. (St. Louis, MO). The minimum
inhibitory concentration (MIC) for each tested antibiotic was
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determined by the standard broth microdilution method in
MHB broth (supplemented with 50 mM CaCl2 for daptomycin) as previously described by the Clinical and Laboratory
Standards Institute (CLSI) standards to define the susceptibility or resistance of the strains tested [43]. The MIC for
each antibiotic combination was determined by the checkerboard broth microdilution method as previously described
[44–46]. We used rifampicin or gentamicin as an adjuvant
with daptomycin, vancomycin and linezolid and used for the
combination treatment in this study. The fractional inhibitory concentration (FIC) index value, which was used to
determine if the combination of antibiotics was synergistic,
additive, indifferent, or antagonistic, was calculated as
previously described [43, 45, 46].
Minimum biofilm eradication concentration (MBEC) assay

The susceptibilities of biofilms (USA300 LAC, the
msaABCR deletion mutant, and the complementation
strains) to antibiotics were tested using a static MBEC 96
biofilm assay as described in the manufacturer’s manual
(MBEC™-HTP assay, Innovotech Inc.) [47]. Briefly, an
overnight culture of each bacterial strain was diluted to an
absorbance value of 0.05 at OD600 in fresh biofilm media
and inoculated (200 μl) onto the MBEC plate. The biofilm
was allowed to grow at 37 °C on the pegs under shaking
conditions (150 rpm) for 24 h. After 24 h incubation, three
pegs for each strain tested were harvested to assess the
biofilm. The remaining pegs were then transferred to a
plate that contained 10×, 20×, 40×, or 80× MIC of tested
antibiotics concentration. The plate also contained a set of
control experiment where the biofilm is allowed to grow
in media without antibiotics. The biofilms were further incubated at 37 °C under shaking conditions (150 rpm) for
24 h. After incubation, the pegs were rinsed in phosphatebuffered saline (PBS) to remove non-adherent bacteria,
transferred to a new plate containing sterile PBS, and sonicated to remove adherent bacteria. Aliquots (100 μl) of
appropriately diluted samples then were plated on tryptic
soy agar (TSA) and incubated overnight at 37 °C prior to
enumeration. All experiments were performed in triplicate
and repeated three times.
Persister assays

Exponential phase cells were prepared as described above.
When an OD600 reached 0.5, 100 μL of each culture was
removed, serially diluted in 900 μL of 1× phosphate buffer
saline (PBS) and plated for colony forming units (CFUs)
for the initial count. The remaining cultures were individually challenged with daptomycin (10 μg/ml; 10×
MIC), vancomycin (25 μg/ml; 40× MIC), linezolid (50 μg/
ml; 10× MIC), gentamicin (20 μg/ml; 4× MIC) and rifampicin (2.4 μg/ml; 40× MIC) and further incubated at 37 °C
with continuous shaking (225 rpm). We used the minimum concentration of each antibiotic that showed similar
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killing kinetics to that of higher concentrations of the respective antibiotic. At designated time points of antibiotic
exposure, 100 μL of cells was removed, washed with
900 μL of 1X PBS and plated for CFUs counts after 24 h
of incubation. Stationary phase cells were prepared as described above. Similar to the exponential phase, 100 μL of
the culture was used for the initial CFUs count while
remaining was challenged with antibiotics daptomycin
(80 μg/ml, 80× MIC), vancomycin (125 μg/ml, 200×
MIC), linezolid (100 μg/ml, 20× MIC), rifampicin (4.8 μg/
ml, 80× MIC) and gentamicin (25 μg/ml, 5× MIC). Accordingly, persister assay was performed in exponential
and stationary phase culture with combination of the antibiotics. The concentrations of antibiotics used in single
and combination are listed in Additional file 1: Table S1
and Additional file 2: Table S2. All the experiments were
performed at least in three biological replicates.
To confirm whether the isolated persister cells show similar behavior during the antibiotic treatment, the persister
cells were harvested and regrown in fresh media and again
treated with antibiotics. We chose vancomycin and vancomycin/rifampicin to represent the single and combination
antibiotic experiments respectively. We harvested the
persister cells fractions after 48 h post-treatment with vancomycin and 72 h post-treatment with vancomycin/rifampicin.
The cells were washed in 1X PBS, inoculated in MHB, regrown and exposed subsequently to the respective antibiotics. CFUs were counted and line graph was plotted to
observe whether the re-treatment assays show the identical
biphasic killing as the initial experiments. This re-treatment
experiment was performed consecutively for 4 times.
Catheter based-biofilm Persister assays

An in vitro catheter-associated model of biofilm formation
was used to perform persister assay under biofilm conditions as previously described [48]. The concentrations of
antibiotics (individual and combined) tested for this assay
are listed in Additional file 3: Table S3. In brief, 1-cm segments of fluorinated ethylene propylene (FEP) catheters (14
gauge; Introcan Safety, B. Braun, Bethlehem, PA, USA)
were cut in half with sterile scissors and then placed in the
24-well microtiter plate and coated overnight with 20% human plasma (Sigma-Aldrich, Inc., St. Louis, MO). The catheters (3 per well) were transferred to wells containing 2 mL
of biofilm medium with respective test strains (USA300
LAC, msaABCR deletion mutant, and the complementation strain) normalized to an OD600 of 0.05. The catheters
were further incubated at 37 °C with shaking for 24 h, the
catheters were removed, rinsed in PBS to remove nonadherent bacteria, and placed into fresh biofilm medium
supplemented with 2.5 mM CaCl2 with or without the indicated amounts of antibiotics, and incubated for up to four
days. Each day, catheters (n = 3) were recovered, and the
spent medium was replaced with fresh medium (containing
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2.5 mM CaCl2 with or without the indicated amounts of
antibiotics). The procedure continued till day 4. To enumerate the surviving cells after antibiotic treatment, each
day, the catheters (3 per day) were harvested to enumerate
the number of CFUs per catheter. The catheters were
rinsed with 1× PBS to remove non-adherent bacteria and
placed into a test tube containing 2 mL of sterile 1× PBS,
after which they were sonicated to remove adherent
bacteria. Aliquots (100 μl) of appropriately diluted samples
were then plated on TSA and incubated overnight at 37 °C
prior to enumeration. All experiments were performed in
triplicate and repeated three times.

Bioflux based – Biofilm persister assay

S. aureus biofilm development was assessed using a BioFlux200 microfluidic system (Fluxion Biosciences, Inc.,
San Francisco, CA, USA) as described previously [49].
Using BioFlux200 24-well plates, the biofilm growth channels were first coated overnight at 4 °C with human
plasma. The channels were then primed with pre-warmed
(37 °C) biofilm media; excess TSB was aspirated carefully
from the output and input wells. To seed the channels
with bacteria, the output wells were replaced with 200 μl
of fresh overnight-cultured S. aureus cells diluted to an
OD600 of 0.1 and pumped into the channels at 2.0 dynes/
cm2 for 7 s. The cells were then allowed to attach to the
channel surface of the plate for 1 h at 37 °C. The excess
inoculum was aspirated from the output well, and 1.5 mL
of biofilm media was added to input well A. Biofilm media
supplemented with 50 mM CaCl2 and appropriate antibiotics was added to input well B. Input well A was pumped
for 12 h at the rate of 0.6 dyne/cm2, and input well B was
maintained to a pressure of 0.0125 dyne/cm2 to withstand
the backflow of media. The pump pressure was reversed
after 12 h to assess the effect of the antibiotics on the preformed biofilm under continuous flow. Bright-field images
were acquired in 10- or 20-min intervals for 2 days using
an inverted microscope (Leica DM IL LED Fluo Inverted
Microscope; Leica Microsystems) under 5X magnification.
For this assay, we tested the same concentrations of the
antibiotics as were described above for the in vitro
catheter-based biofilm assay (Additional file 3: Table S3).
All the experiments were repeated three times.

Quantification of acquired BioFlux biofilm images

Using BioFlux Montage software (Fluxion Biosciences,
Inc.), the bright-field images were analyzed as previously
described by Moormeier et al. [49]. A threshold was set to
include all light images (biofilm cells) using the Threshold
tool and Slider tool. The percentage of biofilm coverage
was calculated as the total percentage of area coverage by
the biofilm and was plotted against the time frame.
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RNA isolation and RNA sequencing

Total RNA for RNA sequencing (RNA-seq, HiSeq 2000)
was isolated from cells using a Qiagen RNeasy Maxi
column (Qiagen, Valencia CA), as previously described in
Sahukhal & Elasri [41]. Briefly, overnight cultures of S. aureus were diluted to an OD600 of 0.05 in TSB and incubated
at 37 °C with shaking (200 rpm) until they reached an
OD600 of 1.5. The cells were first treated with RNA protect
(Qiagen, Valencia CA) and were further proceeded for the
RNA extraction. To isolate total RNA under biofilm conditions, the USA300 LAC and msaABCR deletion mutant’s
biofilm were first grown in flow cells (Stovall Life Science,
Greensboro, NC), as previously described in Sahukhal et al.
[40]. The biofilm cells were harvested, treated with RNA
protect (Qiagen) and were further processed for the RNA
extraction. The concentration and the quality of total RNA
was determined by Nanodrop spectrometer readings, as
well as using a Bioanalyzer (Agilent). Only those RNA
samples that have an A260/A280 ratio of ~2.0 and an RNA
Integrity number (RIN) value of ≥9.7 were used for further
processing. The total RNA was processed using
MICROBExpress™ Kit (Ambion, AM1905) to enrich bacterial mRNA by removing the 16S and 23S ribosomal RNA
from the total RNA as instructed in the MICROBExpress™
kit life technologies protocol. The concentration and the
quality of enriched RNA was determined by using a Bioanalyzer (Agilent). The RNA was stored at −80 °C and
shipped to Beckman coulter genomics center in dry-ice for
RNA-sequencing using Illumina- HiSeq 2000. The data
generated form the HiSeq200 was aligned to NC_007793.fa
(Staphylococcus aureus subsp. aureus USA300_FPR3757,
complete genome) by using Tophat-2.0.8b [50, 51]. The
transcript level counts were calculated and FPKM normalized using Cufflinks-2.1.1 [52, 53]. An FPKM filtering cutoff
of 1.0 was used to determine expressed transcripts and
differential expression of genes in the msaABCR deletion
mutant compared to wild type USA300 LAC was computed using Cuffdiff. All the genes that are differentially
expressed greater than 3-fold were considered significant
and were used for further GO enrichment analysis.
Comparative gene ontology analysis

As a part of functional genomic analysis of our RNA-seq
transcriptomics data, we performed gene ontology (GO) classification of differentially expressed genes (≥ 3-fold). We used
freely available web-based GO analysis tool (Comparative
GO, [54]) to better understand the differentially expressed
genes in terms of biological pathways involved so that we
can select some important genes for further analysis.
Statistical analysis

All statistical analyses to test significance in this study were
done by using OriginPro software (Originlab, Northampton,
MA). The statistical significance level 0.05 was set as cutoff
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values while performing the statistical analyses. The data obtained from CFU experiments under planktonic growth
phase (exponential- and stationary-) were analyzed using
Student’s t-test. All the results from the biofilm experiments
were analyzed using Student’s t-test and one-way ANOVA
followed by posthoc Tukey’s test.

Results
The msaABCR deletion mutant show no defect in growth
and antibiotic susceptibility

To study the role of the msaABCR operon in the S. aureus
persister cells formation, we first examined if the deletion
of msaABCR operon has any growth defect under planktonic conditions. Our results showed that the msaABCR
deletion mutant has no growth defect in both exponential
and stationary growth phases in nutrient rich media like
MHB (Additional file 4: Figure S1). Therefore, observed
difference in CFUs between the wild type USA300 LAC
and the mutant strains in presence of antibiotics are due to
killing and not growth defects in the mutant. Prior to conducting persister assays, we first determined the susceptibility of the msaABCR deletion mutant to the antibiotics
under both planktonic and biofilm growth conditions. In
this study, we focused on clinically relevant antibiotics
(daptomycin, vancomycin, linezolid, rifampicin, and gentamicin) that are used for the treatment of serious MRSA infections as discussed in the Clinical Practice Guidelines by
the Infectious Diseases Society of America [55]. We used
standard microbroth dilution method and the CLSI standards to define the antibiotic susceptibility or resistance of
the strains tested [43]. We found that deletion of the
msaABCR operon did not influence the susceptibility of S.
aureus to daptomycin, linezolid, or gentamicin. However,
the deletion of the msaABCR operon resulted in a two-fold
decrease in MIC to rifampicin and vancomycin (Table 1).
We also tested the impact of antibiotic treatment within
biofilm on USA300 LAC, msaABCR deletion mutant, and
the complementation strain by using standard 96-well
plate MBEC™-HTP assay. The wildtype USA300 LAC,
msaABCR deletion mutant, and complementation strains
colonized the MBEC pegs at a rate of 1.3 × 107., 5.83 ×
106, and 1.67 × 107. CFUs per peg, respectively after 24 h
(Additional file 5: Fig. S2). These 24 h grown biofilms were
Table 1 Determination of the Minimum Inhibitory
Concentration (MIC) of antibiotics
Antibiotics
tested

Minimum inhibitory concentration (μg/mL)
USA300 LAC

msaABCR

Complementation

Daptomycin

1

1

1

Rifampicin

0.06

0.0312

0.06

Vancomycin

0.625

0.312

0.625

Linezolid

5

5

5

Gentamicin

5

5

5

then treated with daptomycin, rifampicin, vancomycin,
linezolid, or gentamicin at a range of 10× to 80× MIC in
96-well plates. Antibiotic concentrations greater than 80×
MIC were not used as these are beyond the concentrations used in clinical settings. Several antibiotics significantly affected the biofilm grown on the MBEC pegs after
24 h treatment in a dose dependent manner (Fig. 1 and
Fig. 2). Specifically, the biofilm of the msaABCR deletion
mutant was significantly affected when treated with
daptomycin, vancomycin, or linezolid relative to that of
the wildtype USA300 LAC and the complementation
strains (Fig. 1). The msaABCR deletion mutants’ biofilm
was undetectable when treated with 80 μg/mL (80× MIC)
of daptomycin (Fig. 1a). Likewise, the mutant’s biofilm was
reduced by 58- to 87-fold and from 2- to 22-fold when it
was treated with vancomycin and linezolid, respectively (Fig.
1b and c). The difference in CFUs observed in the mutants’
biofilm is statistically significant when analyzed using
Student’s T-test. The statistics were further confirmed by
one-way ANOVA followed by post-hoc Tukey’s HSD test.
However, rifampicin and gentamicin treatment did not have
any significant effect on the msaABCR deletion mutant
relative to wildtype. For control, we added biofilm media
without antibiotics to continue the biofilm growth. Under
control condition, the msaABCR deletion mutant showed a
5.64-fold reduction in its ability to form biofilm relative to
wildtype (Fig. 1). These results showed that although there is
no clear-cutoff MBEC values for all the strains tested, the
msaABCR deletion mutants’ biofilm was significantly
affected by antibiotic treatment.
The msaABCR deletion mutant showed increased susceptibility
towards antibiotics with rifampicin as an adjuvant

Combination of antibiotics therapy not only enhances the
efficacy of treatment [56–59] but also reduces the incidence of resistance against monotherapy [60]. In clinical
practice, rifampicin or gentamicin were used as an adjuvant therapy to daptomycin, vancomycin, or linezolid [55,
59, 61]. Therefore, we assessed the impact of antibiotic
combinations under both planktonic and biofilm conditions by using in-vitro checkerboard microbroth dilution
method. We calculated the FIC index for each combination as defined by the Antimicrobial Agents and Chemotherapy journal definitions of synergy (FIC index of ≤0.5)
and antagonism (FIC index of >4.0) [62]. Our result
showed that in all three combinations of antibiotics that
included rifampicin showed synergistic activity with FIC
index values of less than 0.05 on planktonic cells (Tables 2
and 3). The combination of rifampicin and daptomycin
had the greatest synergistic activity with an FIC index of
0.176 against the wildtype strain and an FIC index of
0.079 against the msaABCR deletion mutant (Tables 2 and
3). When gentamicin was used as an adjuvant, we did not
observe any synergistic activity, except in the case of the
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Fig. 1 Antibiotic susceptibility in biofilm. USA300 LAC, msaABCR deletion mutant, and the complementation strains biofilm were grown on
MBEC™-HTP plates and treated overnight with 10X to 80X MIC of a. daptomycin, b. vancomycin or c. linezolid. These results represent the means
of three independent experiments performed in triplicate. Control in each experiment represents the biofilm grown in regular biofilm media
without antibiotics. Error bars represent SE. Student’s t-test and one-way ANOVA followed by Tukey’s test (OriginPro) was used to compare the
results of the wild-type to mutants (* p-value <0.05, ** p-value <0.005)

daptomycin/gentamicin combination which showed
synergistic activity against wildtype (Tables 2 and 3).
We also observed that the antibiotic combinations were effective against biofilms in a dose-dependent manner (Fig. 2).
We did not observe any clear cutoff MBEC value for the
combined antibiotic treatment; however, the msaABCR deletion mutant biofilm was significantly reduced relative to the
wildtype biofilm, and this reduction was far more significant
than the corresponding comparison in the absence of antibiotics (5.64-fold). When rifampicin was combined with daptomycin, vancomycin, or linezolid, the msaABCR deletion
mutant biofilm was reduced by 142- to 619-fold, 10- to 246fold, or 17 to 270-fold, respectively, relative to wildtype biofilm (Fig. 2a, b, and c). In contrast, the msaABCR deletion
mutant biofilm showed a reduction from 3.4- to 11-fold, 5.9to 14-fold, and 6- to 22-fold in biofilm formation when
gentamicin was combined with daptomycin, vancomycin, or
linezolid, respectively (Fig. 2d, e, and f). This is particularly
interesting since combinations that included gentamicin did
not have any synergistic effects on the msaABCR deletion
mutant under planktonic conditions (Table 3). These results
indicate that antibiotic combinations that include rifampicin
as an adjuvant are significantly more effective against the

msaABCR deletion mutant in both biofilm and planktonic
growth conditions relative to wildtype and the complementation strains. The difference in CFUs observed in the mutants’
biofilm is statistically significant when analyzed Students
T-test. The statistics were further confirmed by one-way
ANOVA followed by post-hoc Tukey’s HSD test.
The msaABCR operon deletion mutant is defective in
persister cells in planktonic growth

In S. aureus, the rate of persister cell formation is dependent
on growth phases [13, 19, 21]. Studies have shown that the
majority of cells at stationary growth phase are slow- or
non-growing and show characteristics that are similar to
those of persister cells [19, 21]. Therefore, we sought to
examine the impact of msaABCR operon-deletion in persister cell formation in both exponential and stationary
growth phases by subjecting the cells to different antibiotic
stress (Additional file 1: Table S1, Additional file 2: Table S2,
and Additional file 3: Table S3). Under conditions without
antibiotics, the msaABCR deletion mutant has no observable growth defect (exponential or stationary) relative to
wild type USA300 LAC (Additional file 4: Figure S1a and
S1b). However, the msaABCR deletion mutant was defective
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Fig. 2 Susceptibility of S. aureus biofilm to combinations of antibiotics. Strains USA300 LAC, msaABCR deletion mutant, and the complementation
biofilm were grown on MBEC™-HTP plates and treated overnight with antibiotic combinations: a. daptomycin/rifampicin, b. vancomycin/
rifampicin, c. linezolid/rifampicin, d. daptomycin/gentamicin, e. vancomycin/gentamicin, or f. linezolid/gentamicin. Antibiotics amount used are
multiples of the combined MIC of the combination. These results represent the means of three independent experiments performed in triplicate.
Control represents biofilm grown without antibiotics. Error bars represent SE. Student’s t-test and one-way ANOVA (OriginPro) followed by Tukey’s
test was used to compare the results of the wild-type to mutants (* p-value <0.05, ** p-value <0.005)

in persister cells in most of the antibiotics tested during exponential growth phase. Daptomycin (10×) rapidly killed
majority of all the cells tested within 2 h of treatment. The
persister plateau was observed in USA300 LAC and the
complementation strains after 6 h post treatment till
24 h, however no visible CFU were detected in the
msaABCR deletion mutant post 2 h treatment till 24 h,
suggesting a defect in the formation of persister cells by
the mutant in presence of daptomycin (Fig. 3b; Table 4).
Likewise, the numbers of persister cells was decreased
Table 2 MIC of in vitro combinations of antibiotics by the
checkerboard broth microdilution method
Minimum inhibitory concentration (μg/mL)
DAP / RIF

USA300 LAC

msaABCR

Complementation

0.0312 / 0.0078

0.0156 / 0.0039

0.0312 / 0.0078

VAN / RIF

0.156 / 0.0075

0.039 / 0.0075

0.156 / 0.0075

LIN / RIF

0.156 / 0.0037

0.156 / 0.00094

0.156 / 0.0037

DAP / GEN

0.0195 / 1.25

0.312 / 1.25

0.0195 / 1.25

VAN / GEN

0.312 / 1.25

0.312 / 1.25

0.312 / 1.25

LIN / GEN

0.3125 / 2.5

0.039 / 2.5

0.3125 / 2.5

DAP: daptomycin, VAN: vancomycin, RIF: rifampicin, LIN: linezolid,
GEN: gentamicin

by 55-fold relative to the wildtype within 16 h of rifampicin treatment while 23-fold reduced persister cells
were observed with vancomycin treatment for 48 h
(Fig. 3e and c; Table 4). But, the msaABCR mutant
formed similar proportion of persister cells as that of
wild type strains with linezolid treatment for upto 72 h
(Fig. 3d; Table 4). Gentamicin showed the highest killing rate forming persister plateau from 2 to 6 h, where
the msaABCR deletion mutant formed 12.5-fold reduced persister cells relative to wild type, however, no
visible CFU were observed post 6 h treatment in all the
strains tested (Fig. 3f; Table 4).
We also tested the effect of antibiotic combinations on
the persister cell formation during the exponential
growth phase. Our results show that antibiotic combinations: daptomycin/rifampicin, vancomycin/rifampicin,
and daptomycin/gentamicin significantly reduced the
persister cells (>10 fold) in the msaABCR deletion mutant relative to the wildtype (Fig. 4a, b, and d; Table 4).
Vancomycin/gentamicin combination also significantly
reduced the persister cells in the mutant relative to its
wild type and complementation strains, however, the
persister plateau was observed from 4 to 8 h treatment,
and no detectable CFU were observed post 8 h
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Table 3 Fractional Inhibitory Concentration (FIC) values for combined antibiotics as defined by CLSI standards
FIC Index
DAP / RIF

USA300 LAC

Complementation

msaABCR

FIC

FIC range

INT

FIC

FIC range

INT

FIC

FIC range

INT

0.176

0.162–0.193

SN

0.079

0.07–0.08

SN

0.176

0.162–0.193

SN

VAN / RIF

0.354

0.31–0.375

SN

0.27

0.187–0.375

SN

0.35

0.31–0.37

SN

LIN / RIF

0.246

0.18–0.315

SN

0.13

0.002–0.3

SN

0.25

0.18–0.32

SN

DAP / GEN

0.346

0.269–0.437

SN

0.54

0.52–0.56

AD

0.346

0.269–0.437

SN

VAN / GEN

0.87

0.75–1.0

AD

0.87

0.75–1.0

AD

0.87

0.75–1.0

AD

LIN / GEN

0.54

0.51–0.56

AD

0.511

0.507–0.515

AD

0.54

0.51–0.56

AD

DAP: daptomycin, VAN: vancomycin, RIF: rifampicin, LIN: linezolid, GEN: gentamicin, INT: interpretation; SN: synergy (FIC ≤ 0.5); AD: additive (> 0.5 FIC ≤ 1.0); IN:
indifferent (1.0 > FIC ≤ 4.0); AN: antagonistic (FIC > 4.0)

treatment (Fig. 4e). Interestingly, the msaABCR deletion
mutant showed 14-fold increased CFUs relative to wild
type in response to linezolid/gentamicin combination,
but we did not observe peculiar persister plateau fraction until 24 h of treatment (Fig. 4f; Table 4).

Our persister cells assay, during the exponential growth
phase, in presence of individual as well as combination of
antibiotics stress showed different killing kinetics and
formed their characteristic persister plateau. Previous
studies have shown that regular as well as persister cells of

Fig. 3 Persister cells in exponential growth phase. Strains USA300 LAC, msaABCR mutant and the complementation were grown to exponential
growth phase. Strains were then exposed to high concentration of antibiotics: a. no antibiotic control, b. daptomycin (10 μg/ml, 10× MIC), c.
vancomycin (25 μg/ml, 40× MIC), d. linezolid (50 μg/ml, 10× MIC), e. gentamicin (20 μg/ml, 4× MIC), and f. rifampicin (2.4 μg/ml, 40× MIC). Time 0 h
represents antibiotic exposure point. These results represent the means of three independent experiments. Error bars represent SE. Student’s t-test
(OriginPro) was used to compare the results of the wild-type to mutants at respective designated time points (* p-value <0.05, ** p-value <0.005)
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Table 4 Comparison of the rate of persister cell formation
between the msaABCR deletion mutant and wildtype USA300 LAC
Fold change in persister cells formation (mutant vs. wildtype)
Antibiotics Exponential Growth
phase

Stationary Growth
phase

Biofilm

DAP

UD**

- 2.15

- 747.11**

VAN

- 23.82**

- 1.40

2.8X104**

RIF

- 54.16**

- 1.66

- 19.56

LIN

- 1.18

- 44.67**

- 14.24**

GEN

- 12.50**

UD**

- 2.33

DAP + RIF - 25.03**

- 23.02**

UD**

VAN + RIF - 96.12**

- 4.04

- 32.35**

LIN + RIF

1.47

- 3.35

- 4.32

DAP +
GEN

- 55.30*

- 53.88**

- 0.73

VAN +
GEN

- 13.23**

- 0.88

- 406.66**

LIN + GEN

+ 14.43**

- 9.43**

- 37.50**

started to decrease until 16 h (Fig. 3). Post 16 h of rifampicin
treatment all tested strains started developing adaptive resistance (data not shown).
To confirm whether the isolated persister cells will show
similar trajectory of killing curve to their respective initial
treatments, we performed re-treatment experiments with
vancomycin and vancomycin/rifampicin to represent the
single and combination antibiotic treatments respectively.
For this, the persister cells harvested after 48- or 72 h were
washed in 1X PBS and re-inoculated in fresh MHB. The
cells were regrown and treated with respective antibiotics
exactly to their initial experiment. These re-treatments
continued for four consecutive cycles and CFUs counts
from each re-treatment was plotted. We found the identical
biphasic killing as well as similar significant differences in
persister cells between the wild type and mutant strains to
their respective initial experiment results (Additional file 6:
Figure S3). These results confirm that the msaABCR
deletion mutant is defective in persister cells, and the difference in CFUs between the USA300 LAC and the
msaABCR deletion mutant is not due to difference in resistance patterns.

DAP: daptomycin, VAN: vancomycin, RIF-rifampicin, LIN: linezolid, GEN:
gentamicin, UD: undetectable persister cells in the msaABCR deletion mutant
Statistically significant (* p-value <0.05, ** p-value <0.005): The difference in
CFUs observed in the mutant cells Vs wild type cells was analyzed by students
T-test to measure the statistical significance. All the CFUs experiments that
involved the biofilm cells were analyzed by one-way ANOVA followed by
post-hoc Tukey’s HSD test to measure the statistical significance

Stationary phase S. aureus cells show less tolerance to
gentamicin and its combination

S. aureus are comprised of physiologically heterogeneous
groups [63, 64]. This heterogeneity of fitness resulted in
variety of killing curves, such that in our study, we observed biphasic killing trajectories in some of the drugs
tested while the others were not as pronounced as the
former. For instance, daptomycin in exponential phase,
rapidly killed wild type, msaABCR deletion mutant and
complementation strains cells within 2 h, thus sorting for
highly robust persister cells. We did not observe detectable
CFUs in the msaABCR mutant until 24 h of exposure, while
3 log of wild type and complementation cells remained viable forming a persister plateau. Similarly, pronounced biphasic killing was observed in gentamicin treatment, which
killed 5 log of cells of all the strains within two hours. Steady
number of CFUs were observed for wild type and complementation strains for 6 h of gentamicin treatment, however,
decreasing number of CFUs count in the msaABCR mutant
demonstrate the presence of less tolerant persister cells in
the mutant. The killing curve in vancomycin treatment was
not as pronounced as the formers. Moreover, the steady decreasing number of CFUs count in the msaABCR mutant
after 24–48 h of treatment shows the presence of less tolerant persister cells in the mutant relative to wild type and the
complementation strains that showed the presence of robust
persister cells. Similarly, robust persister cells were isolated
in wild type and complementation strains within 12–16 h of
rifampicin treatment, while mutant cells only formed transient persister plateau for 12–14 h of treatment, after which it

Previous studies have shown that stationary phase S. aureus cells are extremely tolerant to conventional drugs behaving as persister cells [10, 65, 66]. We studied the
persister cells by all the strains in presence of different
antibiotic stress during the stationary growth phase. We
observed that both the wild type and msaABCR deletion
mutant were highly tolerant to vancomycin (200×), and
rifampicin (40×) treatment (Fig. 5c and e). Daptomycin
(80×) treatment killed most of the stationary phase cells
(all three strains tested), and showed smooth killing curve
thus forming distinct persister plateau after 48 h of
exposure, however, there is no significant difference in the
persister cells between USA300 LAC and msaABCR deletion mutant (Fig. 5b). Interestingly, the msaABCR deletion
mutant cells are completely reduced to an undetectable
level with gentamicin treatment. Gentamicin (5×) treatment rapidly killed stationary phase msaABCR mutant
cells within 12 h of treatment, resulting into 1.72X104-fold
reduced persister cells relative to wild type. No detectable
CFUs were observed in the msaABCR deletion mutant
after 24 h post-treatment with gentamicin, whereas 5 log
of CFUs were still observed in the wild type cells until
48 h of treatment (Fig. 5f). In fact, this is the only antibiotic
against which no persister cells were detected in the stationary phase msaABCR mutants’ cells. Similarly, the stationary
phase msaABCR deletion mutants’ cells formed 44.67-fold
less persister cells relative to the USA300 LAC when treated
with linezolid (20×) for 72 h (Fig. 5d). This contrasts with exponential growth phase cells where linezolid treatment
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Fig. 4 Persister cells in exponential growth phase in presence of combined antibiotic treatment. The exponentially growing cells (USA300 LAC,
msaABCR mutant and the complementation) were treated with combined antibiotics. a. daptomycin/rifampicin (40× MIC), b. vancomycin/
rifampicin (20× MIC), c. linezolid/rifampicin (20× MIC), d. daptomycin/gentamicin (20× MIC), e. vancomycin/gentamicin (20× MIC), and f.
linezolid/gentamicin (20× MIC). Student’s t-test (OriginPro) was used to compare the results of the wild-type to mutants at respective designated
time points (* p-value <0.05, ** p-value <0.005). These results represent the means of three independent experiments. Error bars represent SE

showed no difference between USA300 LAC and msaABCR
deletion mutants’ persister cells.
When we challenged the stationary cells with antibiotic
combinations, we observed a pronounced biphasic killing
curve dependent on the combination treatments (Fig. 6).
The msaABCR deletion mutant showed 23-fold reduced
persister cells relative to its wild type and complementation
strains when treated with daptomycin/rifampicin, but the
wild type and complementation strains were not much
affected, suggesting the presence of more tolerant cells in
these strains (Fig. 6a). Daptomycin/gentamicin combination
was found most effective in killing the stationary phase cells
and the msaABCR deletion mutant showed 54-fold reduced
persister cells relative to its wild type and the complementation strains (Fig. 6d). Likewise, linezolid/gentamicin combination was also found most effective in killing the stationary
phase cells and reduced the rate of persister cells formation

in the msaABCR mutant by 9.5-fold (Fig. 6f). However,
vancomycin/gentamicin combinations did not show any effect on the stationary phase cells of all strains tested (Fig.
6e). Other antibiotic combinations (vancomycin/rifampicin
and linezolid rifampicin) also did not have any difference in
the level of persistence between the msaABCR deletion mutant and the USA300 LAC strains (Fig. 6b, and c; Table 4).
We also tested the persister phenotype after msaABCR deletion in Vancomycin Intermediate S. aureus (VISA) strain
Mu50 in planktonic growth phase (exponential and stationary) after treatment with Daptomycin (10X MIC, 20 μg/ml).
Our results showed that deletion of msaABCR operon in
Mu50 background significantly reduced the persister cells in
both exponential and stationary growth phases in presence
of daptomycin (Additional file 7: Figure S4). Thus,
msaABCR operon is involved in persister cells formation in
both MRSA and VISA S. aureus strain background.
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Fig. 5 Persister cells from stationary phase growth. Strains USA300 LAC, msaABCR mutant, and the complementation were grown to stationary
growth phase and then exposed to high concentrations of antibiotics. a. no antibiotic control. B. daptomycin (80 μg/ml, 80× MIC), c.
Vancomycin (125 μg/ml, 200× MIC), d. Linezolid (100 μg/ml, 20× MIC), e. rifampicin (4.8 μg/ml, 80× MIC) or f. gentamicin (25 μg/ml, 5× MIC).
These results represent the means of three independent experiments. Error bars represent SE. Student’s t-test (OriginPro) was used to compare
the results of the wild-type to mutants at respective designated time points (* p-value <0.05, ** p-value <0.005)

The msaABCR mutant shows reduced persister cells in biofilm

Biofilms have been shown to be an important source of
persister cells [4, 10, 13, 21]. In previous studies, we have
shown that msaABCR deletion mutant forms weak and
loose biofilms, and are defective in late stages of biofilm formation (biofilm maturation). However, they are not defective in early stages of biofilm formation (attachment and
accumulation). This led us to speculate that the loose and
weak biofilm produced by msaABCR deletion mutant may
not capable of maintaining persister cells within the biofilm.
We measured the rate of persister cell formation in all three
strains in intravenous catheter based biofilm conditions. Before studying persister cells in biofilm conditions, we first
assessed the biofilm formation by the USA300 LAC,
msaABCR deletion mutant and the complementation
strains on the intravenous catheters for four days without
antibiotic treatment. We observed that the msaABCR deletion mutant formed 2.3-fold reduced biofilm after day 1

and day 2, and 4.40-fold reduced biofilm after day 3 and
day 4, relative to USA300 LAC (Fig. 7a). The number of
CFUs on catheter for the USA300 LAC and msaABCR deletion mutant were 4.89X108 and 2.13X108 respectively
after day 1, and thus used this time point for antibiotic
treatment to study the persister cells. (Fig. 7a). We initiated
the biofilm formation on the intravenous catheters for 24 h,
and then a continuous antibiotic treatment was applied for
four days (Figs. 7 and 8). Bacterial CFUs were determined
on a subset of catheters each day after antibiotic treatment.
Bacterial CFUs were also determined on subset of catheters
prior to the initiation of antibiotic treatment (day 0).
We observed pronounced biphasic killing curves in
biofilms of all strains when challenged with all antibiotics
(individual and combinations) except with rifampicin (40×)
treatment, where we observed adaptive resistance after one
day of exposure (Fig. 7d). With daptomycin (20×) treatment, the wildtype strain generated 1.34X106 persister cell
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Fig. 6 Persister cells from stationary phase growth using combined antibiotics. The cells from stationary growth phase (USA300 LAC, msaABCR
mutant and the complementation) were treated with combinations of antibiotics. a. daptomycin/rifampicin (320× MIC), b. vancomycin/rifampicin
(40× MIC), c. linezolid/rifampicin (160× MIC), d. daptomycin/gentamicin (30× MIC), e. vancomycin/gentamicin (20× MIC), and f. linezolid/
gentamicin (20× MIC). These results represent the means of three independent experiments. Error bars represent SE. Student’s t-test (OriginPro)
was used to compare the results of the wild-type to mutants at respective designated time points (* p-value <0.05, ** p-value <0.005)

by the end of four days of continuous treatment, while the
msaABCR deletion mutant generated significantly fewer
persister cell, 1.80X103, thus representing a 747-fold reduction relative to the wildtype strains (Fig. 7b). Vancomycin
(20×) treatment produced the highest killing rate in the
msaABCR deletion mutant biofilm and showed 1.27X104fold reduction in persister cells relative to USA300 LAC
(Fig. 7c). Linezolid (20×) treatment had the least killing effect and generated relatively high rates of persister cell;
8.25X105 in the msaABCR deletion mutant and 1.17X107
in USA300 LAC (Fig. 7e). Treatment with gentamicin
(20×) generated very less persister cell in both wild type
USA300 LAC and msaABCR deletion mutant strains after
one day of treatment, but interestingly, no detectable persister cells were observed in any of the strains after day 2 of
treatment (Fig. 7f).
The antibiotic combinations were found most effective
against the msaABCR deletion mutants’ biofilm and required

significantly less antibiotic concentrations relative to individual antibiotic (Additional file 3: Table S3). We found that
after four days of continuous treatment, daptomycin/rifampicin (160×) effectively reduced the number of persister cells
generated by the msaABCR deletion mutant to an undetectable level relative to USA300 LAC (Fig. 8a). Vancomycin/
gentamicin (20×) and vancomycin/rifampicin (40×) also significantly reduced the number of persister cells generated by
the msaABCR deletion mutant by 407-fold and 32-fold, respectively relative to the USA300 LAC strain after four days
of continuous antibiotic treatment (Fig. 8e and b). Linezolid/
gentamicin (40×) combination reduced the persister cells
from the msaABCR deletion mutants’ biofilm by 37.50-fold
relative to USA300 strains after day 3 treatment, however,
after day 4 treatment, no detectable CFUs were observed in
all strains (Fig. 8f). Other antibiotic combinations like linezolid/rifampicin (40×) and daptomycin/gentamicin (40×) treatment resulted into similar fractions of persister cells in all of
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Fig. 7 Persister cells on biofilms. Strains USA300 LAC, msaABCR deletion mutant, and the complementation were allowed to form biofilm on
intravenous catheters for 24 h. Biofilm were then exposed to high concentration of antibiotics. a. no antibiotic control, b. daptomycin (20 μg/ml, 20×
MIC), c. vancomycin (12.5 μg/ml, 20× MIC), d. rifampicin (4.8 μg/ml, 80× MIC), e. linezolid (100 μg/ml, 20× MIC), and f. gentamicin (100 μg/ml, 20×
MIC). The arrow in the no antibiotic control (a.) represents the starting point for the antibiotic treatment in the tests. These results represent the means
of three independent experiments performed in triplicate. Error bars represent SE. Student’s t-test and one-way ANOVA (OriginPro) followed by Tukey’s
test was used to compare the results of the wild-type to mutants at respective designated time points (* p-value <0.05, ** p-value <0.005)

the strains tested (Fig. 8c and d). Therefore, combined antibiotics treatment increases the killing rate of cells growing in
biofilm conditions generating comparatively less persister
cells, with msaABCR deletion mutant being more susceptible
relative to the individual antibiotic treatments. All the results
were analyzed with Students t-test as well as with one-way
ANOVA followed by Tukey’s HSD test to confirm the results
from t-test to effectively evaluate the differences between the
wild type and mutants’ biofilm under controlled and antibiotics treatment conditions.
The msaABCR deletion mutant is defective in persister
cells under continuous antibiotic treatment condition

We observed significant defect in persister cells formation
by the msaABCR deletion mutants’ biofilm under static invitro catheter based biofilm model. We further confirmed
these results by studying the effect of antibiotics treatment

in biofilm under continuous flow condition by using BioFlux 200 system (Fluxion Biosciences Inc.) and a 24-well
microfluidic plate device. Biofilms were formed in BioFlux200 24-well plates and monitored by bright field microscopy every 10 min for 3 days using an inverted
microscope (Leica DM IL LED Fluo Inverted Microscope;
Leica Microsystems). In the absence of antibiotics, the wildtype and the complementation strains formed similar biofilm. Cells attached to the surface after inoculation (0 h),
and biofilm formation increased gradually for 15 h. A rapid
accumulation of biofilm was observed at 13 h postinoculation. After this step, the mature biofilm underwent
periodic cycles of sloughing off and maturation every 4–
5 h. The msaABCR mutant showed similar biofilm growth
pattern to wild type USA300 LAC strain till 15 h. After
15 h, the msaABCR mutants’ biofilm was significantly
dropped to 12.5% compared to that of the wildtype, 76.42%
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Fig. 8 Persister cells from biofilms treated with combinations of antibiotics. Strains USA300 LAC, msaABCR deletion mutant, and the
complementation were allowed to form biofilm on intravenous catheters for 24 h and then treated with combined antibiotics. a. daptomycin/
rifampicin (80× MIC), b. vancomycin/rifampicin (40× MIC), c. linezolid/rifampicin (320× MIC), d. daptomycin/gentamicin (40× MIC), e. vancomycin/
gentamicin (20× MIC), f. linezolid/gentamicin (20× MIC). These results represent the means of three independent experiments performed in
triplicate. Error bars represent SE. Student’s t-test and one-way ANOVA (OriginPro) followed by Tukey’s test was used to compare the results of
the wild-type to mutants at respective designated time points (* p-value <0.05, ** p-value <0.005)

(Additional file 8: Figure S5). This is consistent with our
previous studies, which showed that the msaABCR deletion
mutant fails to develop a mature biofilm [40, 41]. We selected the 12-h time point at which to introduce antibiotics
and to examine the effect of continuous antibiotic treatment on biofilm growth and the emergence of any persister
cells. We tested the same antibiotics and concentrations as
described above for the in vitro catheter-based biofilm assay
(Additional file 3: Table S3). Biofilms formed by the
msaABCR deletion mutant that were treated with a continuous flow of antibiotics (20× of daptomycin, vancomycin, or linezolid) were readily cleared immediately after
their introduction relative to USA300 LAC biofilms. However, the msaABCR deletion mutant still developed some
small colonies after 38 h of post continuous treatment with
both daptomycin and linezolid. These colonies persisted
until the end of the experiment. Continuous treatment with

rifampicin (20×) or gentamicin (20×) showed no impact on
any of the strains tested (data not shown). Representative
figures for daptomycin and vancomycin treatment are
shown in Additional file 9: Figure S6 and Additional file 10:
Figure S7 respectively.
We also tested the combination of antibiotics in the Bioflux biofilm model. Continuous daptomycin/rifampicin
(160×), vancomycin/rifampicin (40×), and vancomycin/gentamicin (20×) treatments reduced the msaABCR deletion
mutant biofilm after 12 h to undetectable levels compared
with the USA300 LAC biofilm. Continuous linezolid/rifampicin (40×) and linezolid/gentamicin (40×) treatments produced a similar impact in all the strains tested; however,
daptomycin/gentamicin (40×) had the least effect on the
msaABCR deletion mutant relative to USA300 LAC. Representative figures for daptomycin/rifampicin and vancomycin/rifampicin are shown in Additional file 11: Figure S8
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and Additional file 12: Figure S9 respectively. The results
from treating the biofilms with antibiotics in the Bioflux
system were consistent with the in vitro intravenous catheter biofilm results. Therefore, our findings show that the
msaABCR deletion mutants’ biofilm is unable to persist
under treatment by some antibiotic combinations and is
easily cleared compared with the wildtype USA300 LAC
strain under the same treatment conditions.
Genes related to formation of persister cells are
differentially regulated by msaABCR

Previous studies have shown that several metabolic genes,
transport, signaling, and oxidative-stress-related genes play
role in the formation of persister cells in S. aureus [19, 21,
30, 38, 67, 68]. We conducted a genome-wide RNA-seq
analysis of the msaABCR mutant relative to wild type during the mid-exponential growth phase. We found that 238
genes were differentially expressed in the mutant at 3-fold
or higher relative to wild type. Comparative Gene Ontology
analysis of msaABCR RNA-seq transcriptomics data
showed that msaABCR operon plays role in the regulation
of genes that are involved in metabolisms (amino acids,
carbohydrate, fatty acids, nucleotides), transporters, Signaling and oxidative stress, and Enzymes (Proteases, hydrolases and nucleases) (Fig. 9; Additional file 13: Table S4).
We found a total of 31 genes that plays role in metabolism
were differentially expressed (>3 fold). Of 31 metabolic
genes found in our analysis, 14 genes are involved in carbohydrate metabolism, 6 genes are involved in amino acid
metabolism, 7 genes are involved in fatty acid metabolism,
and 4 genes are involved in nucleotide metabolism (Fig. 9;
Additional file 13: Table S4). Deletion of msaABCR also affected the expression of 8 transcription factors. Of those,
sarA, SAUSA300_0265, SAUSA300_0750, SAUSA300_
0878, and SAUSA300_2156 play important roles in virulence, cell growth, metabolism, quorum sensing, and biofilm development [48, 69–74]. A total of 20 genes that
plays role in transport: phosphate, sodium ion, ferrous ion,
nickel/cobalt ion, cation, polyamines, drug, carbohydrate,
and amino-acid were affected. Several genes that play roles
in cell-signaling, maintaining homeostasis, oxidative stress
and SOS response were also affected (Fig. 9; Additional file
13: Table S4). Regulation of enzymes plays important role
maintaining the normal physiology of cells. Several enzymes
like hydrolases, metalloproteases, serine and cysteine proteases, endoribonucleases, nucleases, oxidases and reductases
were also affected by the deletion of msaABCR operon.
Several ATP and GTP binding proteins and/or enzymes (20
genes) were also affected. A total of four genes that plays an
important role in cell-wall biosynthesis (femA, femB, mraY,
and murD) were affected (Additional file 13: Table S4).
We also studied the transcriptomics of msaABCR deletion
mutant under biofilm conditions. We found 26 genes that
were differentially expressed in the mutant. Three genes that
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plays role in amino-acid metabolism (purQ, ald, and ilvA)
and the pur operon genes (purC, purD, purE, purF, purH,
purK, purL, purM, purN, purQ, and purS) that plays important role in ‘de novo’ IMP biosynthetic process were affected.
Others genes that plays role in cell death (lrgA and lrgB),
transmembrane transport, PTS system (mannitol specific
IIBC component), metalloaminopeptidase, formate dehydrogenase, and Oxygen-dependent choline dehydrogenase were
also affected (Additional file 14: Table S5).
These findings suggest that the msaABCR deletion mutant is defective in regulating genes that are important for
metabolism, proteases and hydrolases enzymes, transporter systems and other global regulators that may play
roles in maintaining dormancy during the persister stage.
In the future, we plan to further examine the direct or indirect regulation of these genes by msaABCR operon and
define a mechanistic role during persister cells formation.

Discussion
Antibiotic treatment failures are becoming increasingly
problematic, and potential solutions can range from finding
new antibiotics to improving the effectiveness of existing
ones. Several chronic infections caused by S. aureus are difficult to treat because of the emergence of persister cells,
which are genetically sensitive to antibiotics but are not
killed by them [10, 16, 75]. However, the mechanism for
this antibiotic tolerance and persister cells formation is still
not well understood, especially in S. aureus. Previously, our
laboratory characterized the msaABCR operon and showed
that it plays a key role in virulence, autolysis and biofilm development [40, 41]. We have also shown that msaABCR
operon increased the susceptibility of VISA strains to
vancomycin and is involved in cell wall synthesis [42]. More
recently we showed that MsaB, the protein produced from
msaABCR operon is a transcription factor, that binds its
target DNA in response to nutrient availability [39]. These
findings led to this current study to examine the role of the
msaABCR operon in the S. aureus persister cells formation
in presence of antibiotics stress since persister cells
formation is related to nutrient response to some extent.
Here, we show that deletion of the msaABCR operon in
USA300 LAC not only increased the efficiency of drugscombination but also formed significantly less number of
persister cells in planktonic as well as biofilm growth conditions. Importantly, the concentration of antibiotics used in
the combination treatments, which significantly impacted
both persister cell formation and biofilm viability in the
msaABCR deletion mutant, are within the concentrations
defined by the CLSI as the breakpoint MICs for MRSA
strains of S. aureus.
This study demonstrates the role of the msaABCR operon
in persister cells development and survival in S. aureus under
antibiotic stress. This adds a new regulator into the limited
body of knowledge about the mechanism of persister cells
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Fig. 9 Comparative gene ontology analysis of msaABCR transcriptomics by for RNA-sequencing using Illumina- HiSeq 2000. The data was aligned by
using Tophat-2.0.8b [50, 51]. Cufflinks-2.1.1 [52, 53] was used to measure the transcript level. Cuffdiff was used to determine expressed transcripts and
measure the differential expression of genes in the msaABCR deletion mutant compared to wild type USA300 LAC. All the genes that are differentially
expressed greater than 3-fold were considered significant and were analyzed by web-based GO analysis tool (Comparative GO) [54]

formation in S. aureus. We showed that the deletion of the
msaABCR operon significantly reduces the rate of persister
cell formation in all growth phases: exponential, stationary,
and biofilm. The trajectories of killing curves and formation
of characteristic persister plateau observed was dependent
on growth phases and the particular antibiotics used
(individual or combinations). This may be because previous
studies have shown the presence of physiologically heterogeneous groups of populations among the cells of S. aureus
[63, 64]. For instance, during exponential growth phase, all
individual and combined antibiotic tested showed good trajectories of killing curves and the msaABCR deletion mutant
formed significantly less number of persister cells relative to
wild type. However, linezolid, linezolid/rifampicin and linezolid/gentamicin did not show any significant difference between wild type and mutant strains, and showed high
number of robust persister cells in all strains tested. The retreatment experiment in which the persister fraction obtained was re-inoculated in fresh media and again treated

with the antibiotics showed similar trajectory of killing kinetics confirms that remaining cells after the initial treatments
are persister cells and not resistant cells.
Consistent with previous studies related to persister
cells in S. aureus, we also observed significant number
of cells that are extremely tolerant to antibiotic treatment during the stationary growth phases. We found
most of the antibiotic treatment (individual or combinations) used in this study generated significant number of
persister cells during stationary growth phase. Daptomycin treatment killed most of the stationary phase cells;
however, the numbers of persister cells are similar in all
strains. Importantly, gentamicin treatment reduced the
persister cells in the msaABCR deletion mutant to an
undetectable limit within 12 h, whereas robust persister
cells are still present until 48 h in the USA300 LAC.
Furthermore, daptomycin/gentamicin and linezolid/gentamicin treatments were also found very effective in killing stationary phase S. aureus cells, with the msaABCR
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deletion mutant being killed more and thus resulting
into significant drop in persister cells in the mutant relative to USA300 LAC and complementation strains. In
addition, significant reduction in persister cells in the
msaABCR deletion mutant in VISA strain (Mu50) background when treated with daptomycin under both exponential and stationary growth phases suggest that this effect
is strain independent. However, more strains need to be analyzed to ensure that the role of the msaABCR operon in
formation of persister cells is conserved in S. aureus.
In biofilm growth conditions, we observed the pronounced effect of msaABCR operon deletion. The mutants’ biofilm was severely defective in persister cells by
several orders of magnitude compared to the USA300
LAC with all antibiotics treatment. However, with rifampicin treatment, we observed increased resistance patterns
after day 1 treatment. A similar phenomenon was observed by Raad et al. [76], who found that treatment with
rifampicin alone is not sufficient for reducing the microbial burden in catheter-associated biofilms and that such
treatment is associated with the emergence of rifampicin
resistance in MRSA strains. The same study also showed
that rifampicin in combination with other antibiotics is
successful in eliminating biofilms [76]. We reasoned that
the defective biofilm in the msaABCR deletion mutant,
characterized by loosely connected matrix may not be favorable to formation of persister cells. However, further
studies are needed to understand these observations or
the mechanism used by msaABCR in antibiotic tolerance.
Mechanism of formation of persister cells has been
studied well in E. coli, pseudomonas, and Mycobacterium
tuberculosis but relatively little is known about mechanisms in S. aureus. Yee et al. [38] recently studied the role
of metabolism (purine, amino acid, carbohydrate, Lipid,
vitamins), proteases and hydrolases, and transporters in
the persistence in presence of rifampicin. Conlon et al.
[19] showed that depletion of intracellular ATP is important for the S. aureus persister cell formation. In USA500
strains, genes essential in TCA cycle, such as sdhA, sdhB
and sdhC, were found to reduce the persister cells [77].
Small colony variants (SCVs) in S. aureus were found
more tolerant to the antibiotics due to defective electron
transport chain specifically heme and menaquinone synthesis deficiency [78]. In addition, pathways activated in
SCVs were also upregulated in persister cells [79], which
suggest that changes in metabolic pathways lead to slowgrowth and consequent persistence in S. aureus. Indeed,
persistence appears to be the extensively dependent on
bacterial metabolism [31, 67, 80]. All these results indicate
the importance of metabolic processes, energy production,
and transporter genes etc. in the persister development
and survival in S. aureus.
Our transcriptomics data suggest that the msaABCR
operon may control the expression of genes that may be
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involved in the formation of persister cells. Under planktonic
growth condition, we showed that this operon affects the expression of several genes including transcription factors,
metabolic genes, transporters genes, ATP and GTP binding
protein encoding genes and cell wall biosynthetic genes.
Several genes that have been previously linked with persister
cells formation in other bacterial systems like superoxide
dismutase [Mn/Fe]2, iron-sulfur cluster assembly scaffold
protein NifU, pyruvate oxidase, ketol-acid reductoisomerase, phosphate ABC transporter/permease protein
PstA, serine protease, cysteine proteases and metalloproteases were also affected by the deletion of msaABCR operon
[10, 30, 31, 36, 67, 81–83]. Under the biofilm growth conditions, the pur operon was differentially expressed in the
msaABCR mutant. Previously, Yee et al. [38] showed that
the pur operon plays role in persister cells formation in
presence of rifampicin treatment in S. aureus. Additionally,
defective purine biosynthesis has been linked to the defective
biofilm formation in other bacterial systems like Streptococcus sanguinis [84] and in Burkholderia [85]. The defective
and immature biofilm formation in msaABCR deletion mutant is mediated through the increased processing of major
autolysin, Atl, by excessive protease production which led to
uncontrolled cell death. However, further studies are needed
to determine whether the excessive protease production also
resulted in the defect of formation of persister cells in the
msaABCR mutant. Likewise, whether the msaABCR operon
plays role in formation of persister cells regulating the purine
genes also remains to be elucidated. Other genes that plays
role in amino-acid metabolism, programmed cell death,
transmembrane transport and metalloaminopeptidase were
also affected in msaABCR mutants’ biofilm. However, these
findings are just the initial steps in defining the mechanism
of persister cell formation in S. aureus by msaABCR operon
and further studies are needed to define the mechanistic role
of the msaABCR operon in the S. aureus antibiotics response
and/or persistence.
Overall, these results suggest that targeting the msaABCR
operon leads to reduced formation of persister cells in
MRSA strains in both planktonic and biofilm growth conditions. More importantly, the concentration of antibiotics
in the combination treatments, that significantly impacted
both persister cell formation and biofilm viability in the
msaABCR deletion mutant, are within the concentrations
defined by the CLSI as the breakpoint MICs for MRSA
strains of S. aureus. Thus, inactivation of the msaABCR
operon might enhance the effectiveness of antibiotics used
in the treatment of MRSA infections, especially in context
of persister cells.

Conclusions
In this study, we have shown that msaABCR operon
plays role in the persister cells formation in S. aureus.
We have also shown that the persister cell formation in
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S. aureus is dependent on the growth phases (exponential,
stationary, and biofilm) and type of antibiotic treatment applied (Individual Vs Combined). This is evident by the different trajectories of killing curves generated by different
antibiotics treatment under different growth conditions.
Stationary and biofilm growth conditions of S. aureus are
known to the most favorable physiological niche for the
persister cells and presumed to be very tolerant to most
traditional drugs. Importantly, we have shown that deletion
of msaABCR operon significantly affected the persister cells
formation under stationary growth phases with antibiotics
treatment like gentamicin, daptomycin/gentamicin and linezolid/gentamicin. In addition, the msaABCR deletion
mutant is severely defective in persister cells formation
under biofilm growth conditions when treated with almost
all individual and combined antibiotics, except rifampicin
and daptomycin/gentamicin treatment. We also showed
that deletion of msaABCR operon regulates the expression
of several genes that are important in metabolism,
virulence, transports, cell wall metabolism and several
transcription factors. However, we have not yet defined the
exact mechanism by which msaABCR exerts its role in
persister cells formation, but we seek to define the mechanism in future. Thus, this study provides additional insight
into a limited body of knowledge about the mechanism of
persistence in S. aureus.
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and bright-field images were collected at every 10 m intervals using an
inverted Leica DM IL LED Fluo Inverted Microscope under 5X magnification.
The media with antibiotics flow rate was set at 64 μl/h and biofilm was
monitored up to 50 h. a. Area coverage of biofilm. b. Representative images
of biofilm development at different time points (TIFF 10521 kb)
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